AstraZeneca has extended a contract to use a digital health device developed by ImpediMed that is being deployed in a trial of two of its drugs in chronic kidney disease (CKD).
Medtech giant Beckton Dickinson (BD) has signed a deal with France's Biocorp to use the latter's near-field communication (NFC) tags in injectable devices.
An explosion of digital mental health tools being offered for sale has presented regulators with a problem – how should they be classified and assessed for safety or efficacy?
In future, blood samples may be taken by an autonomous robot rather than a healthcare professional – if Dutch developer Vitestro can get its prototype approved for marketing.
